Denosumab treatment for osteoporosis raises the risk for hypocalcemia, which worsens with advancing stages of chronic kidney disease (CKD), in those with CKD–Mineral and Bone Disorder (CKD-MBD) and in ...

The researchers found that with denosumab vs oral bisphosphonates, the risk for emergently treated hypocalcemia increased with worsening CKD stage. (HealthDay News) — For patients with chronic kidney ...

Colored x-ray of the pelvic region shows a fractured femur (red) caused by a fall. A lack of clinical trials and limited pharmaceutical options mean that management of this complication poses ...

Trends suggest that clinical practice could be driven heavily by providers’ preferences and beliefs, resulting in substantial practice variation. Management of chronic kidney disease mineral bone ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...

Please provide your email address to receive an email when new articles are posted on . Patients with diabetes mellitus had higher aortic pulse wave velocity levels vs. patients without diabetes.

Findings showed treatment with Prolia significantly increased the risk of developing severe hypocalcemia compared with bisphosphonates, especially in patients with advanced CKD. In patients with ...

Credit: Getty Images In a study, intact parathyroid hormone levels below 60 and above 1500 pg/mL were associated with nearly double the risk of all-cause mortality. High or low levels of calcium, ...

The bisphosphonates are used widely in osteoporosis. In patients with stage 4 CKD, one small study found a modest increase in the bone density of the spine after 18 months, but no change in the hip. 7 ...